Effectiveness and feasibility of a software tool to help patients communicate with doctors about problems they face with their medication regimen (EMPATHy): study protocol for a randomized controlled trial by John Billimek et al.
Effectiveness and feasibility of a software tool to
help patients communicate with doctors about
problems they face with their medication regimen
(EMPATHy): study protocol for a randomized
controlled trial
Billimek et al.
Billimek et al. Trials  (2015) 16:145 
DOI 10.1186/s13063-015-0672-7
TRIALS
Billimek et al. Trials  (2015) 16:145 
DOI 10.1186/s13063-015-0672-7STUDY PROTOCOL Open AccessEffectiveness and feasibility of a software tool to
help patients communicate with doctors about
problems they face with their medication regimen
(EMPATHy): study protocol for a randomized
controlled trial
John Billimek1*, Herlinda Guzman1 and Marco A Angulo2Abstract
Background: Low-income, Mexican-American patients with diabetes exhibit high rates of medication nonadherence,
poor blood sugar control and serious complications, and often have difficulty communicating their concerns about the
medication regimen to physicians. Interventions led by community health workers, non-professional community
members who are trained to work with patients to improve engagement and communication during the medical
visit, have had mixed success in improving outcomes. The primary objective of this project is to pilot test a prototype
software toolkit called “EMPATHy” that a community health worker can administer to help patients identify the most
important barriers to adherence that they face and discuss these barriers with their doctor.
Methods/Design: The EMPATHy toolkit will be piloted in an ongoing intervention (Coached Care) in which
community health workers are trained to be “coaches” to meet with patients before the medical visit and help
them prepare a list of important questions for the doctor. A total of 190 Mexican-American patients with poorly
controlled type 2 diabetes will be recruited from December 2014 through June 2015 and will be randomly assigned to
complete either a single Coached Care intervention visit with no software tools or a Coached Care visit incorporating
the EMPATHy software toolkit. The primary endpoints are (1) the development of a “contextualized plan of care” (i.e., a
plan of care that addresses a barrier to medication adherence in the patient’s daily life) with the doctor, determined
from an audio recording of the medical visit, and (2) attainment of a concrete behavioral goal set during the
intervention session, assessed in a 2-week follow-up phone call to the patient. The statistical analysis will include
logistic regression models and is powered to detect a 50% increase in the primary endpoints.
Discussion: The study will provide evidence regarding the effectiveness and feasibility of a software tool to help
patients communicate with doctors about problems they face with their medications.
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Although numerous effective and affordable medication
therapies for diabetes exist, and others are being developed,
the true impact on health of the best available medications
is greatly limited by widespread medication nonadherence
[1,2]. Even as access to health care continues to improve
nationwide, only 19% of diabetic patients have attained rec-
ommended targets for glycemic control, lipid levels and
blood pressure [3], and around 50% struggle to adhere to
their medications [2,4]. This is especially problematic for
low-income, ethnic minority patients who face challenging
life circumstances that make adherence difficult [5-8] and
who, not surprisingly, suffer the worst health outcomes
[9,10]. Even those who gain access to health insurance
often do not realize improved outcomes [11]. This can
be explained largely by poor medication adherence [10]
and a lack of health care that is responsive to barriers in
patients’ daily lives [12].
Nonadherence is a highly heterogeneous set of behav-
iors [13], and the reasons people deviate from their regi-
mens vary considerably [14]. Reasons for nonadherence
include high out-of-pocket costs, forgetting to take the
medication, difficulties obtaining refills, concerns about
side effects, doubts about the necessity of the medication
and other unfavorable beliefs about taking the medication
[5,14,15]. Numerous interventions and resources to help
promote adherence, such as pharmacist-led medication
management clinics and cell phone-based reminders, are
available [16,17], but to have maximum effect, the right
intervention should be matched to the specific barriers an
individual is facing [13].
It is no surprise, therefore, that effective doctor-patient
communication is associated with better regimen adher-
ence [18]. It leads to patients who are more engaged in
the medical decision-making process and are therefore
more likely to follow through with their regimen and attain
better clinical outcomes [19,20]. Furthermore, it allows the
patient to engage in a discussion of his or her personal life
circumstances and allows the physician to tailor the regi-
men to a specific patient’s circumstances [21-23], which
has been shown to promote improved outcomes [24].
Despite these benefits, and recent guidelines recommend-
ing that providers consider patient’s life circumstances
when developing a treatment plan for diabetes [25], there
is often not enough time in a 15-minute visit to discuss all
the possible barriers to adherence. On average, patients
discuss six health issues with their doctor in each visit
[26], but only address the non-medical, “contextual” bar-
riers to adherence (such as costs, confusion and health
beliefs) in 8% of visits [27]. For many patients, it is diffi-
cult to communicate with providers about barriers [28],
especially when there are language and cultural differ-
ences [10]. Unfortunately, these visits are short and busy
[26], and patients—especially those from disadvantagedpopulations—often do not communicate effectively with
providers about their specific barriers to medication ad-
herence [10,28].
Empowering patients to prepare in advance of their
visit to identify their most important barriers to adherence
may promote a focused discussion of those barriers that is
feasible during a short, busy medical visit. Community
health worker (CHW)-led interventions show promise to
improve adherence and outcomes by promoting better
patient-provider communication, but to date have pro-
duced mixed results [29]. CHWs are “non-clinical”members
of a health care team who come from similar backgrounds
in terms of ethnicity, language, socioeconomic status and life
experiences as the patients they serve [30]. CHWs have
been employed widely to provide culturally appropriate
health education in diverse settings [31]. Although well-
trained CHWs exhibit excellent cultural competency, iden-
tifying the most important issues to address in a complex
regimen remains a challenge for providers at all levels of
training [32]. CHW-led interventions maybe improved by
introducing a component to structure the discussion and
prioritization of barriers to medication adherence.
A computer-assisted approach may improve the ability
of patients and CHWs to work together to identify and
prioritize key barriers to adherence prior to the medical
visit. Such approaches can be designed to be inexpensive
and to require minimal additional training, while making
better use of the patient’s wait time prior to the doctor
visit [33].
We hypothesize that a computer-assisted intervention
combining a software toolkit to guide the discussion of
barriers to medication adherence with an existing CHW-
led patient participation training intervention [34] will
help patients communicate effectively with doctors about
problems they face with their medication regimens. In
this article, we describe this software tool, the EMPATHy
Toolkit, and the protocol for a randomized controlled trial
to assess the feasibility and effectiveness of the tool.
Objectives
The primary objective of this project is to pilot test
“EMPATHy,” a prototype software-based toolkit in a
previously developed CHW-led intervention (Coached
Care) that is ongoing at the study site with a highly vul-
nerable population—low-income Mexican-American pa-
tients with diabetes and a history of nonadherence.
Results from this pilot study will be used to estimate
the key parameters necessary to design a definitive trial
and ascertain the feasibility and usability of the EMPATHy
toolkit.
All study comparisons will be between patients randomly
allocated to a “Coached Care + EMPATHy” group versus
those assigned to a control group (“Routine Coached Care”
with no software).
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Aim 1. Evaluate the preliminary impact—after a single
intervention visit—of EMPATHy on doctor-patient
communication about problems patients are facing with
their medication regimens. We hypothesize that compared
to controls, patients in the “Coached Care + EMPATHy”
condition will:
1.1 Be more likely to raise a relevant “contextual factor”
(i.e., a barrier to medication adherence in daily life)
with the doctor, determined using a validated audio
coding scheme [35] to analyze an audio recording
of the medical visit.
1.2 Be more likely to leave the medical visit with a
“contextualized plan of care” (i.e., a plan of care
that addresses the contextual factor raised during
the visit), determined using the same audio coding
scheme.
Aim 2. Evaluate the impact of EMPATHy on patient
follow-through with the plan of care developed during
the medical visit with the doctor. We hypothesize that
compared to controls, patients in the “Coached Care +
EMPATHy” condition will:
2.1 At 2-week follow-up, be more likely to have
attained a concrete behavioral goal identified during
the intervention visit.
2.2 By the next regularly scheduled medical visit, be
more likely to show improvement in the “red flag”
health outcome (A1c, LDL or blood pressure)
identified during the intervention visit.
Aim 3. Assess and describe the feasibility, acceptability
and usability of EMPATHy.
Methods/Design
Study design
This study is a randomized controlled trial allocating par-
ticipants to complete either the standard Coached Care
intervention (routine coached care intervention with no
software enhancement and unstructured discussion of
barriers) or enhanced Coached Care (the Coached Care +
EMPATHy software to structure discussion of barriers).
Standard Coached Care is a program offered to eligible
patients with diabetes at the study site and therefore is
considered routine care.
Study setting
Participants will be recruited from a primary care clinic in
a university-affiliated federally qualified health center in
Santa Ana, California. The center predominantly serves
low-income, ethnic minority patients from the community.
Interventions
The EMPATHy toolkit will be pilot tested in the context
of a previously developed CHW-led intervention knownas Coached Care. The Coached Care intervention is a
CHW-led patient participation training intervention de-
veloped and tested in a prior study [34]. Patients in the
program are paired with CHW “coaches,” matched to
the patient’s language and ethnicity. The coaches meet
with patients immediately prior to their medical visits to
discuss barriers the patient is facing. The objective of a
coaching session is to help the patient develop helpful
questions to ask the physician about specific barriers
and to provide training to help the patient ask the ques-
tions confidently and effectively.
Coaches are recruited through job postings posted on
the medical center “Careers” website and in advertise-
ments posted throughout the clinic. Coaches are not re-
quired to have formal education beyond a high school
diploma or equivalent or to have experience working in
a health care setting. For coaches recruited to work at
sites with many patients who speak a language other than
English, bilingual proficiency in that language is required.
“A personal connection” to a chronic health condition is
listed as a preferred qualification.
Newly hired coaches complete 4 days of standard
“on-boarding” training required of all clinic employees
on topics including confidentiality, safety, data security
compliance and using the electronic medical record and
other computer systems. They then complete online train-
ing modules in motivational interviewing, “teach-back”
methods for patient education and an introduction to
diabetes and heart failure. Next, they complete 2 days
of classroom training discussing the etiology, symptoms
and management of the chronic conditions that will be
the focus of their work (diabetes and heart failure) and
the principles of patient participation training (discussing
barriers to disease management, formulating questions for
the doctor, coaching the patient to discuss their questions
effectively, etc.). They then complete 2 weeks of on-site
training in the clinics with the intervention coordinators
and have continuing education activities at least once per
quarter.Study intervention (Coached Care + EMPATHy software)
Participants allocated to the study intervention will
complete a Coached Care intervention visit enhanced by
completing a tablet computer-based activity using the
EMPATHy toolkit. The conceptual model for EMPATHy
is grounded in the Information-Motivation-Behavioral Skills
(IMBS) model of medication adherence [36], which
suggests that for a patient to adhere to a medication
regimen, he or she requires (1) information—an under-
standing of what needs to be done, (2) motivation—a be-
lief that adherence will produce a worthwhile benefit and
(3) behavioral skills—strategies and resources to overcome
barriers to adherence (see Figure 1).







Figure 2 Sample vignettes from the Education Module (EM).
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(1) a computer-based interactive Educational Module (EM)
to convey information about the complex set of benefits
and burdens associated with a disease management regi-
men; (2) a Preference Assessment (PA) module to help the
patient identify and prioritize the most important barriers
that outweigh the perceived benefits of taking medications;
and (3) a Tailored Help (TH) module using the results
from the PA to guide the coach to teach behavioral
skills tailored to help patients overcome those high pri-
ority barriers.
1. Education Module (EM). The EM consists of a set
of vignettes describing each of a set of commonly
experienced barriers to medication adherence.
The vignettes present each barrier in practical
terms as a real person’s experience of a barrier
(e.g., describing how a person might be affected
by concerns about costs or doubts about the
safety of the drug; see Figure 2 for example).
Broad themes for barriers to include in the Education
Module materials were identified from a literature
review and interviews with patients, physicians,
diabetes educators and other experts, then vetted
by an advisory group of patient stakeholders. For
each barrier, a brief educational page was written
at a sixth grade reading level and translated fromEnglish to Spanish by a team of natively fluent,
trained translators. For this prototype tool, the
EM materials are presented as a series of simple
web pages in Spanish and English with navigation
buttons to move from topic to topic in any order
selected by the patient. Navigation through the
topics is driven by the patient and is facilitated by
the coach who is trained in the use of the EM.2. Preference Assessment (PA) module. The PA module
was developed using a commercially available
preference assessment software package
(SSI Web v.8.3, Sawtooth Software, Orem, UT).
The PA module applies a preference assessment
method known as maximum difference scaling
(MDS or “best-worst” scaling), guided by best
practices for stated-preference assessment
methods for conjoint analysis and discrete choice
experimental methods [37]. Sawtooth Software
allows MDS tasks to be run and analyzed on desktop
and mobile devices with no specialized programming
knowledge and has been successfully used in many
settings, including in studies of patients with very
low socioeconomic status [38]. The PA has been
tailored to the appropriate level of literacy, numeracy,
health literacy and graphical literacy for the population
we work with [39,40].
MDS methods are useful to identify the “most
important” elements of a decision or situation for
an individual [41,42]. They are less cognitively
demanding than most preference assessment tasks
(such as rank ordering a long list of options),
requiring the respondent to consider just a few
options at a time. They are less vulnerable to
certain biases than simple tasks such as “pick one”
tasks (e.g., “Name the most important barrier to
Figu
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the importance of individual options better than
asking a respondent to rate their importance on a
numeric scale (e.g., when someone is asked to “rate
on a 1 to 10 scale how important each of these
things are to you,” they tend to rate several things as
very important, but do not identify the most
important thing). MDS, on the other hand, is an
excellent approach to help individuals identify the
one or two most important barriers to discuss with
the doctor because it allows them to consider an
array of possible barriers head to head against each
other, a few barriers at a time, several times each, to
see which issues “rise to the top” as the most
important [41].
Low socioeconomic status patients have a difficult
time identifying the most important topics to
discuss with the doctor and often end up not
discussing any barriers to adherence during the visit.
Even if the task does not identify the true “most
important barrier” for a given patient, we posit that
the activity will at least start a discussion about
barriers with the doctor that will encourage
developing a plan of care that addresses challenging
life circumstances.
The MDS task created for the Preference Assessment
(PA) module includes the barriers described in the
EM. The MDS task presents four of these barriers
at a time, in random order, and asks the patient to
indicate which barrier would be the most helpful to
discuss during the visit, and which would be least
helpful. A total of nine pages with new combinations
of four barriers are presented until one or two
high-priority barriers are identified (see Figure 3
for a sample page).3. Tailored Help (TH). The ultimate intended use of
the EMPATHy toolkit is as an application that can
be integrated with the protocol of any CHW-led
intervention to provide “tailored help” to the patient.
Intervention coordinators would first identify whichre 3 Sample screenshot, in English, of a page in the Preference Aelements of their intervention (resources, programs,
educational materials, etc.) would be most helpful to
address each type of barrier included in the EM and
PA modules. These “best options” for each barrier
type would be noted in the software. Then, in
intervention visits, the CHWs would use the toolkit
to assess the high-priority barriers for each patient
and then provide a tailored response consisting of
the “best option” intervention elements to address
that barrier.
For this project, we will test the effectiveness of
incorporating EMPATHy with the Coached Care
intervention. In the Coached Care intervention, the
main product of each coaching encounter is a tailored
list of questions for the physician about the barriers to
adherence faced by the patient. The TH module for
this prototype will consist of a set of recommended
questions for the physician that match each barrier
evaluated in the PA. During the intervention session,
the CHW coach will refer to this set as he or she
helps the patient come up with a list of questions to
address the patient’s high priority barriers.
Active comparator (standard coached care)
Participants allocated to the active comparator will
complete a standard Coached Care intervention visit
with no computer-based activity. Instead, the patient
and coach will have an unstructured discussion of bar-
riers to adherence. Additional details on the content of
intervention visits for both study conditions can be
found under “Study Procedures.”
Study procedures
The study protocol, delineating routine care activities
(for any patient enrolled in Coached Care at the clinics)
versus additional procedures unique to the study, is sum-
marized in Figure 4. The augmented Coached Care inter-
vention using the EMPATHy toolkit will be pilot tested in
a sample of patients currently eligible to participate in the
UC Irvine Health Coached Care Intervention. Two “study
coaches,” in addition to the coaches providing usual care,ssessment (PA) module.
Figure 4 Protocol summary delineating routine care activities (for any patient enrolled in Coached Care at the clinics) versus additional
procedures unique to the study.
Billimek et al. Trials  (2015) 16:145 Page 6 of 11were hired to conduct all study activities and were trained
in the Coached Care intervention, use of the EMPATHy
toolkit and all study procedures. Both study coaches are
bilingual in English and Spanish and have a bachelor’s de-
gree from a university. Patients enrolled in this pilot study
will be randomly assigned either to complete a single
coaching session using EMPATHy or to complete a single
coaching session with no computer-assisted activity.
Both coaches deliver both versions of the intervention.
Components of the intervention visit and follow-up ac-
tivities are described below.
Sample identification
Participants will be identified from the study site’s diabetes
registry, which includes all adult patients actively receiving
treatment for diabetes at the study site.
Recruitment phone call
The coach will telephone eligible patients who have a
scheduled medical appointment at the study clinic in
the next 21 days. For the study, patients will be askedto meet the coach at the clinic 45 minutes before the
scheduled appointment to discuss the study, give in-
formed consent if interested and complete the pre-visit
coaching session.
Study enrollment
Interested prospective participants will meet with the study
coach in a private area in the clinic to discuss the study
and, if interested, sign a consent form and HIPAA
authorization form. Once informed consent is granted,
the participant will be asked to complete a brief baseline
survey, available in English or Spanish, with questions
about sociodemographic characteristics, barriers to dis-
ease management and medication adherence. Participants
will be assured that they can opt not to respond to any of
the questions. The coach can read questions to any par-
ticipants having difficulty reading the survey.
Pre-visit coaching session
All study participants will complete an intervention visit
based on the routine Coached Care program in which
Billimek et al. Trials  (2015) 16:145 Page 7 of 11patients are paired with a CHW coach, matched to the
patient’s language and ethnicity. In both study conditions,
the coach and patient will review the medical record from
their most recent visit to identify one or more “red flag”
issues related to their disease management such as high
hemoglobin A1c, cholesterol, etc. Patients randomized to
the active comparator (Coached Care with no software
tools) will have an unstructured discussion of barriers
to chronic disease management that may be contribut-
ing to the red flag outcome. Participants randomized to
the study intervention (Coached Care + EMPATHy) will
work with the coach to complete the computer-assisted
activity using a tablet computer. The computer-based
activity, described in more detail under “Study Inter-
vention,” includes a brief Educational Module (EM)
reviewing vignettes of barriers that many patients face,
followed by a Preference Assessment (PA) module to
obtain a rank ordering of the highest priority barriers
that interfere with the patient’s adherence to their
medication regimen and then Tailor Help (TH) to focus
the rest of the visit on the highest priority barriers. In
both conditions, the coach will then employ the ori-
ginal Coached Care protocol to help the patient gener-
ate one to three questions for the physician focusing on
the highest priority barriers and will note these questions
in the Encounter Form.Medical visit
After the intervention visit, the patient will bring the list
of questions into their regularly scheduled medical visit.
With permission of the patient and the physician, the visit
will be audio recorded using a portable digital recorder
that the coach will place in the examination room and
collect after the visit. Before beginning the recording,
the coach will remind the patient that recording the visit
is optional. If either the patient or the physician prefers
that the visit not be recorded, the coach will not record
the visit. In cases where the recording was not done, the
study endpoints that require audio recordings will not be
evaluated for that patient, but the remaining endpoints
will be evaluated from the other data sources. No mem-
bers of the study team will attend the medical visit, but
will wait until after the visit to collect the recorder.Post-visit session
After the medical visit, the patients in both study condi-
tions will meet with the coach to review the list of ques-
tions from the pre-visit coaching session. They will
discuss whether the patient was able to get an answer to
each of the questions and discuss the answers provided.
The coach and patient will then create a plan with spe-
cific actions the patient should take in response to the
answers provided by the doctor. The coach will note inthe Encounter Form which questions were asked, which
were answered and what action steps were recom-
mended. The patient and coach will then set a single,
simple concrete behavioral goal for the patient to
complete in the subsequent 2-week period. This goal will
also be noted in the Encounter Form. Finally, the patient
will complete a brief post-visit questionnaire about the
ease of use of the EMPATHy software (if they used it),
the helpfulness of the coaching session, the relevance of
the issues and concrete goals identified in the coaching
session, and confidence that his or her outcomes will
improve. Immediately upon completing the post-visit
session, the coach will hand the participant a $20 gift
card for compensation.
Two-week follow-up call
Two weeks after the visit, the coach will call each par-
ticipant to review the concrete goal and will document
in the Phone Note whether or not the patient completed
the goal. They will discuss any barriers to completing
the action plan and will encourage the patient to follow
through. Finally, primary nonadherence will be assessed
by asking whether the patient filled all prescriptions
written during the study medical visit. After completing
this phone call, the participant will be given a second
$20 gift card for compensation.
Long-term follow-up
Six months after the intervention visit, the patient’s med-
ical record will be reviewed to obtain the patient’s most re-
cent laboratory values to examine whether the “red flag”
outcome identified in the pre-visit session improved since
the coaching session.
Ethics
The research protocol has been approved by the University
of California Irvine Institutional Review Board (HS#2014-
1441).
Inclusion criteria for patients
Patients will be recruited from the UC Irvine Federally
Qualified Health Center family medicine clinic sites in
Santa Ana and Anaheim with the following inclusion
criteria: (1) age 18 and older; (2) have poorly controlled
type 2 diabetes (as indicated by HbA1c >7.5%, LDL
cholesterol >100 mg/dl or systolic blood pressure >140),
(3) be of Hispanic ethnicity and (4) speak English or
Spanish.
Outcome assessments
Study endpoints will be assessed from (1) analysis of audio
recordings of the patient’s medical visit with the doctor,
(2) the Encounter Form used to document the topics
discussed in the Pre- and Post-Visit Coaching Sessions,
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a “Phone Note,” (4) a brief Post-Visit survey and (5) ab-
straction of laboratory and blood pressure data (HbA1c,
LDL cholesterol and blood pressure) from the electronic
medical record at 6-month follow-up. Participant char-
acteristics, barriers to access and baseline medication
nonadherence will also be assessed with (6) a brief base-
line survey. Study outcome assessments are summarized
in Figure 5.
Primary Outcomes. Two primary outcomes will be
evaluated for this study.
1. Development of a contextualized plan of care will
be assessed by analyzing an audio recording of the
medical visit using a previously developed coding
scheme [35] (see “Analysis of Audio Recordings”).
If the coder concludes that the plan of care
discussed in the visit adequately addresses a
contextual factor raised during the visit, it will beFigure 5 Data collection overview.determined that a contextualized plan of care was
developed.
2. Attainment of a concrete behavioral goal will be
assessed in a 2-week follow-up phone call to the
patient and will be defined as the patient reporting
having completed the specific action that he or she
specified with the Coach as a concrete goal during
the intervention post-visit.
Secondary Outcomes: Two secondary outcomes will be
assessed.
1. Discussion of a contextual factor in the visit will be
assessed from audio recordings of the visit using a
previously developed coding scheme [35]. If the coder
concludes that a relevant barrier to the patient taking
his or her medication consistently was raised during
the visit, it will be determined that a contextual factor
was discussed.
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from the patient’s medical record as the change in
the measured value of the outcome measure identified
as a high priority outcome (“red flag”) from the
intervention visit date till the next regularly scheduled
assessment. The red flag outcome measure is selected
by the Coach and patient during the intervention visit
and can be either hemoglobin A1c, LDL cholesterol
or blood pressure level.
Additional measures
Several measures of feasibility, acceptability and usability
will be collected to describe the participants’ experience
with the software tools and the intervention. The mea-
sures include: the time required to complete the interven-
tion sessions, the patients’ ratings of the ease of use of
the EMPATHy toolkit, confidence to raise the contextual
factor with the doctor, relevance of contextual factors dis-
cussed, the helpfulness of the doctor’s responses, the rele-
vance of the concrete goals during the intervention visit
and confidence that outcomes will improve.
Patient-reported medication adherence will also be
assessed using an 11-item self-report measure of patients’
deviations from the prescribed regimen in the face of
specific barriers [15,34,43]. This measure has been used
in this patient population, is highly correlated with blood
sugar control and LDL cholesterol, and captures both the
extent of nonadherence and reasons for nonadherence.
Additionally, primary nonadherence (failure to fill a pre-
scription) will be collected from patient report during the
2-week follow-up call.
Analysis of audio recordings
Audio recordings of the medical visits will be coded by
members of the research team using a validated method
known as Content Coding for Contextualization of Care
(4C) [35,44] (see Figure 6). The coding method involves
identifying (1) “red flags” or health issues that warrant
discussion of barriers to disease management, (2) whether
a “probe” from the doctor asking about barriers that mayFigure 6 Overview of coding method, Content Coding for Contextualhave contributed to the red flag occurred, (3) whether a
“contextual factor” or specific barrier was raised by the pa-
tients, and (4) whether a “contextualized plan of care” was
created to address the barrier raised. Inter-rater reliability
will be evaluated by having each recording coded by two
separate coders, and then any disagreement between the
raters will be resolved by the lead researcher. Prior studies
using the 4C method have reliably identified how frequently
contextual factors are discussed [27] and shown that pa-
tients who received a contextualized plan of care experience
improved outcomes compared to those did not [24].Statistical analysis
Participant characteristics, including age, gender, educa-
tion, type of medical insurance, nativity and employment
status, will be compared between groups using univariate
statistics. Primary and secondary outcomes are all dichot-
omous (yes or no) outcomes and will be compared be-
tween groups using logistic regression models. Feasibility,
usability and patient-reported barriers to nonadherence
will be presented descriptively.Sample size
The target sample size is 190 (95 participants per group)
to allow us to detect a 50% difference in the rate of occur-
rence of the primary outcome between the intervention
and comparison group with 80% power and an alpha =
0.05. This assumes we observe a base rate of the outcome
of 40% in the active comparator group, as we have ob-
served in an unpublished analysis of data from a prior
study, and 60% in the EMPATHy + Coached Care inter-
vention group.
The sample size calculations do not account for loss to
follow-up because the first primary outcome (development
of a contextualized plan of care) is collected at the sin-
gle intervention visit, and the second primary outcome
(attainment of a concrete behavioral goal) is collected
via telephone after a fairly short follow-up period (2 weeks)
in patients who regularly access the clinic. Results fromization of Care (4C).
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follow-up for a definitive effectiveness trial.Discussion
Numerous studies have employed preference assessment
methods such as conjoint analysis and maximum differ-
ence scaling (MDS) to examine patient preferences about
attributes of available treatment options to help guide
treatment choice. The innovation of the current study
is to apply similar methods not to help select a medication
that is compatible with a patient’s preferences, but to elicit
a discussion of barriers to following the regimen the pa-
tient has already been prescribed.
This is important because a large share of disadvantaged
patients struggle to adhere to their medication regimens,
and it is for reasons that extend beyond out-of-pocket
costs or forgetting to take their pills [5,15]. Although
many patients benefit from programs such as pharmacist-
led medication management clinics and cell phone-based
reminders [17], these interventions cannot be applied un-
less nonadherence is identified [13]. For many patients,
the only opportunity for the health system to identify and
respond to nonadherence is during the medical visit with
the physician. Unfortunately, these visits are short and
busy [26], and patients—especially those from disadvan-
taged populations—often do not communicate effectively
with providers about their specific barriers to medication
adherence [10,28]. By helping patients prepare to discuss
their highest priority barriers to adherence prior to the
visit, approaches like the EMPATHy toolkit may improve
the ability of the health system to recognize nonadherence
and its underlying reasons and to match patients up
with resources and interventions to overcome barriers
to adherence.
Due to its limited scale as a pilot project, the current
study has a number of limitations. First, the study focuses
solely on medication adherence, but not on other import-
ant diabetes management behaviors such as diet, physical
activity and self-monitoring of blood glucose. Second, the
study relies on a single intervention visit to impact the dis-
cussion of barriers to adherence, which may be inadequate
for many patients to give sufficient consideration to their
barriers to identify the most important ones to discuss, or
to feel comfortable discussing barriers at all with a CHW
that they have met only once. Third, there is no objective
assessment of medication adherence using methods such
as medication electronic monitoring system (MEMS) pill
bottle caps that record each time a pill bottle is opened to
take a medication. These limitations can be addressed in
larger scale studies evaluating interventions with a broader
focus, administered over multiple visits, with objective
follow-up measures of adherence. The present study,
however, will provide valuable pilot data to estimate keyparameters to design a definitive trial to test the effective-
ness of approaches like the EMPATHy toolkit.
Trial status
The randomized trial is currently in the phase of participant
enrollment and follow-up.
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